Literature DB >> 2354754

Neuro-ophthalmological evaluation of patients with myelomeningocele and Chiari malformations.

G Lennerstrand1, J E Gallo.   

Abstract

Twenty-eight patients (14 females and 14 males aged between four and 34 years) with myelomeningocele and Chiari malformations were examined neuro-ophthalmologically. All patients had been under proper neurosurgical care and no reduction of visual function was found that could be related to optic atrophy or other changes in the visual pathways. However, ocular motility disorders, including strabismus, were common, although no case of down-beat nystagmus was observed. Manifest strabismus was found in 11 patients. Esotropia with or without A-pattern was seen in nine patients. Spontaneous or gaze-related nystagmus and abnormal optokinetic nystagmus represented the most common disturbances of ocular motility. Abnormalities of horizontal eye-movements were more common than those of vertical eye-movements. Strabismus of the manifest type was combined with other ocular motility disturbances in most cases.

Entities:  

Mesh:

Year:  1990        PMID: 2354754     DOI: 10.1111/j.1469-8749.1990.tb16960.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  3 in total

Review 1.  Cerebellar motor function in spina bifida meningomyelocele.

Authors:  Maureen Dennis; Michael S Salman; Jenifer Juranek; Jack M Fletcher
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

2.  The cerebellar dysplasia of Chiari II malformation as revealed by eye movements.

Authors:  Michael S Salman; Maureen Dennis; James A Sharpe
Journal:  Can J Neurol Sci       Date:  2009-11       Impact factor: 2.104

3.  Vestibular evoked myogenic potentials in children affected by myelomeningocele.

Authors:  Pasqualina M Picciotti; Antonella Fiorita; Lea Calò; Mariapina Battista; Valentina Paolucci; Emanuele Ausili; Luca Massimi; Claudia Rendeli
Journal:  Childs Nerv Syst       Date:  2012-05-05       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.